Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Angiodynamics Inc raises low end of prior FY 2014 revenue guidance; reaffirms FY 2014 EPS guidance; Q3 2014 guidance; EPS guidance above analysts' estimates


Thursday, 9 Jan 2014 04:05pm EST 

Angiodynamics Inc:Says as a result of stronger than anticipated H1 2014.Says for FY 2014 it is raising the low end of revenue guidance to $349 million to $353 million.Says for FY 2014 it expect to report adjusted EPS, excluding amortization, of $0.63 to $0.67 per share, which is consistent with its prior guidance.Says Q3 2014 revenue to range from $85 million to $88 million.Says Q3 2014 adjusted EPS, excluding amortization, is expected to be $0.15 to $0.18 per share.Q3 2014 revenue of $86 million and EPS of $0.10 - Thomson Reuters I/B/E/S Estimates.FY 2014 revenue of $351 million - Thomson Reuters I/B/E/S Estimates. 

Company Quote

15.6
0.31 +2.03%
20 Oct 2014